We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Patient Safety Improved with Reduction in Blood Transfusions

By LabMedica International staff writers
Posted on 28 Oct 2010
Blood transfusions save lives, but they also carry risks. More...
Studies during the past 10 years have found that transfusions make patients more susceptible to infections and increase the risks of poor outcomes such as longer hospital stays, cancer recurrences, and multi-organ system failures.

Transfusions of red blood cells, platelets, plasma, and other blood products were approved decades ago without randomized controlled clinical trials to establish optimal uses. Consequently, doctors sometimes order more transfusions than necessary said Phillip J. DeChristopher, M.D., Ph.D., professor in the Department of Pathology at Loyola University Chicago Stritch School of Medicine and medical director of transfusion medicine, blood bank, and apheresis.
He noted that the amount of plasma transfused per patient in the United States is two to three times higher than the amounts transfused in Canada and Europe.

In a Loyola University study, a new initiative was launched for blood utilization as part of its Blood Management Program. The program implemented blood-use protocols that included evidence-based indications, educational programs for doctors and nurses, and oversight of the Blood Utilization Review Committee.

The study demonstrated how the hospital improved patient safety and cut costs by reducing the number of blood transfusions. These results were reported at the recent annual meeting of the College of American Pathologists, which took place from September 26–29, 2010, in Chicago (IL, USA).

Results of a small clinical trial reported at the American Society of Anesthesiologists annual meeting in San Diego (CA, USA) on October 18, 2010, demonstrated how a new noninvasive continuous blood monitor could reduce the number of blood transfusions given during surgery.

Developed by Masimo (Irvine, CA, USA) the Radical-7 pulse oximeter equipped with continuous hemoglobin monitoring sensors helped anesthesiologists to know whether a patient's blood count is critical without having to wait for lab reports. The results of the trial showed that the real-time blood-monitoring tool could cut the number of transfusions by almost 86%.

Making sure blood transfusions are performed only when necessary would help lower complications from transfusions. Although they save lives, transfusions also carry risks of serious immune reactions. Blood management will also help relieve chronic shortages in the blood supply, especially during summers and holiday seasons when donations drop.

Related Links:

Masimo





Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.